SCHEDULE 13G/A: Baillie Gifford & Co Maintains Significant Stake in Denali Therapeutics, Discloses 8.56% Beneficial Ownership
Beneficial Ownership Disclosure
Baillie Gifford & Co, a UK-based investment adviser, has filed an Amendment No. 7 to Schedule 13G, disclosing its continued beneficial ownership of 8.56% of Denali Therapeutics Inc.'s common stock as of December 31, 2024.
Summary
- Baillie Gifford & Co, an investment adviser based in the United Kingdom, has filed an Amendment No. 7 to its Schedule 13G for Denali Therapeutics Inc.
- As of December 31, 2024, Baillie Gifford & Co beneficially owns an aggregate of 12,313,931 shares of Denali Therapeutics Inc. Common Stock.
- This ownership represents 8.56% of the class of securities.
- Baillie Gifford & Co holds sole voting power over 12,239,731 shares.
- Baillie Gifford & Co holds sole dispositive power over 12,313,931 shares.
- The securities are held on behalf of investment advisory clients, including investment companies, employee benefit plans, pension funds, or other institutional clients, and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investor's continued substantial stake in a biotechnology company, which is a common occurrence in the investment landscape where large asset managers hold diversified portfolios. It does not provide specific insights into Denali Therapeutics' operational performance or strategic direction, but rather reflects an investment position.
Stakeholder Impact
- Shareholders: The continued significant stake by a major institutional investor like Baillie Gifford & Co may be viewed positively by other shareholders as a sign of confidence in the company, although the filing itself is a passive disclosure.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership calculation date) |
| 02/12/2025 | Signature date of the Schedule 13G Amendment No. 7 filing |
Keywords
Denali Therapeutics Inc., Baillie Gifford & Co, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.